Systemic lupus erythematosus (SLE) affects multiple organ systems. While many patients respond to conventional immunosuppressive therapies, some experience treatment-resistant disease, requiring alternative approaches. This research focuses on cell-based therapies that target key immune pathways involved in SLE progression.
Among these therapies, hematopoietic stem cell transplantation (HSCT) has been explored as a means of resetting the immune system. This approach aims to rebuild immune tolerance in patients with severe, refractory disease. Some studies suggest that HSCT may lead to disease remission in certain cases.
Mesenchymal stem cells (MSCs) are another area of interest due to their immunomodulatory properties. Unlike HSCT, MSC therapy does not require immune system replacement but instead works to reduce inflammation and regulate immune responses. Early studies indicate that MSCs may help mitigate disease flares and organ damage.
A more recent approach, chimeric antigen receptor (CAR)-T cell therapy, is being investigated for its ability to specifically target autoreactive B cells involved in SLE pathogenesis. This method, which has been successful in certain hematologic conditions, is being adapted for autoimmune diseases. CAR-T therapy presents an avenue for more precise immune modulation in SLE management.
These therapies may become increasingly viable options for patients with treatment-resistant SLE.
